Nektar Therapeutics (NKTR) Financials: Revenue & Earnings

NKTR price $38.13 +0.16 +0.43%

Ticker
NKTR
Price
$38.13
Change
+0.16 +0.43%
Market cap ?
$1.09B
P/E ?
-5.66
Dividend yield ?
0.00%
Beta ?
1.15
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
45
Value
59
Quality
27
Growth
50

Stocklytics score rationale: value 59, quality 27, growth 50.

Financials

2016201720182019202020212022202320242025
165436000307711000119332300011461700015291500010190700092055000901220009842700055232000

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck…

Fair value

NKTR fair value $2,221.77. Price $38.13. Price is 98% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Model uncertainty high for this stock

Compare NKTR

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-2.07—10.27M
2026-08-13-1.23-1.9710.13M10.43M
2026-05-07-1.82-1.5810.86M10.69M
2026-03-12-1.78-2.4721.81M10.19M
2025-11-06-1.85-2.8511.79M10.05M
2025-08-07-2.95-3.0311.18M9.49M
2025-05-08-3.60-2.5610.46M15.35M
2025-03-120.45-0.1829.18M35.50M
2024-11-07-2.70-2.9924.12M19.18M
2024-08-08-3.75-0.2023.49M18.20M
2024-05-09-2.70-0.1921.64M15.34M
2024-03-04-3.30-0.2123.89M21.43M
2023-11-07-2.85-0.2124.14M21.26M
2023-08-08-4.05-0.2820.50M21.79M
2023-05-09-3.75-0.2521.59M19.41M
2023-02-28-0.32-0.4522.02M22.14M
2022-11-03-3.60-0.4523.62M22.61M
2022-08-04-12.74-14.5521.59M22.62M
2022-05-05-7.35-0.6824.82M24.30M
2022-02-28-0.79-12.0525.01M34.26M
2021-11-04-10.49-11.9924.92M27.82M
2021-08-05-10.34-10.7928.33M25.98M
2021-05-06-10.19-10.7923.65M27.19M
2021-02-25-9.75-10.7923.46M33.58M
2020-11-05-9.15-11.9930.03M36.43M
2020-08-06-6.75-10.3448.85M73.81M
2020-05-07-7.95-12.1450.57M49.92M
2020-02-27-9.60-0.6833.86M35.98M
2019-11-06-8.40-0.7329.22M38.09M
2019-08-08-9.45-0.8023.32M29.61M
2019-05-08-10.19-0.6928.22M28.64M
2019-02-28-8.55-10.4939.83M45.42M
2018-11-07-8.40-9.6027.76M31.23M
2018-08-080.800.801.09B1.07B
2018-05-10-9.00-7.8038.02M34.20M
2018-03-01-2.10-5.7095.47M159.17M
2017-11-075.553.15152.93M106.45M
2017-08-08-5.85-0.3634.59M31.94M
2017-05-09-6.30-0.4224.73M24.70M
2017-03-01-4.20-3.9037.45M34.82M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-23WHITFIELD ROY ABuy2.00K——
2026-09-23WHITFIELD ROY ABuy4.00K$57.66230.64K
2026-09-23GREER R SCOTTBuy2.00K——
2026-09-23GREER R SCOTTBuy4.00K$57.66230.64K
2026-09-23CHESS ROBERTBuy2.00K——
2026-09-23CHESS ROBERTBuy4.00K$57.66230.64K
2026-09-23Brainard DianaBuy4.00K$57.66230.64K
2026-09-23Brainard DianaBuy2.00K——
2026-09-23Ajer Jeffrey RobertBuy2.00K——
2026-09-23Ajer Jeffrey RobertBuy4.00K$57.66230.64K
2026-08-18Zalevsky JonathanSell186$71.9813.39K
2026-08-18ROBIN HOWARD WSell418$71.9830.09K
2026-07-24Zalevsky JonathanBuy16.50K$15.15249.97K
2026-07-24ROBIN HOWARD WBuy57.20K$15.15866.58K
2026-06-30Zalevsky JonathanSell5.68K$70.00397.67K
2026-06-17ROBIN HOWARD WSell5.50K$60.81334.45K
2026-06-17ROBIN HOWARD WSell4.50K$61.65277.43K
2026-06-16ROBIN HOWARD WSell5.30K$59.97318.02K
2026-06-16ROBIN HOWARD WSell4.70K$60.71285.15K
2026-06-15Zalevsky JonathanSell5.54K$60.71336.21K
2026-05-19Zalevsky JonathanSell199$65.5113.04K
2026-05-19ROBIN HOWARD WSell444$65.5129.09K
2026-05-15Rubinstein Linda MOther0——
2026-02-18Zalevsky JonathanSell180$73.0013.14K
2026-02-18ROBIN HOWARD WSell423$73.0030.88K
2026-01-20Zalevsky JonathanSell3.87K$35.67137.94K
2025-12-22Zalevsky JonathanBuy6.25K——
2025-12-22Zalevsky JonathanBuy25.00K$43.481.09M
2025-12-22ROBIN HOWARD WBuy86.67K$43.483.77M
2025-12-22ROBIN HOWARD WBuy21.67K——
2025-11-25Zalevsky JonathanSell1.16K$54.2862.80K
2025-11-25Wilson Mark AndrewSell630$54.2834.20K
2025-11-25ROBIN HOWARD WSell2.21K$54.28119.80K
2025-11-21Zalevsky JonathanBuy2.67K——
2025-11-21Zalevsky JonathanBuy4.77K$281.251.34M
2025-11-21Wilson Mark AndrewBuy1.90K——
2025-11-21Wilson Mark AndrewBuy3.40K$281.25956.25K
2025-11-21ROBIN HOWARD WBuy7.11K——
2025-11-21ROBIN HOWARD WBuy12.17K$281.253.42M
2025-09-30WHITFIELD ROY ABuy8.00K$56.90455.20K
2025-09-30GREER R SCOTTBuy8.00K$56.90455.20K
2025-09-30CHESS ROBERTBuy8.00K$56.90455.20K
2025-09-30Brainard DianaBuy8.00K$56.90455.20K
2025-09-30Ajer Jeffrey RobertBuy8.00K$56.90455.20K
2025-09-09ROBIN HOWARD WSell2.10K$45.1694.84K
2025-09-09ROBIN HOWARD WSell1.20K$46.4155.69K
2025-09-09ROBIN HOWARD WSell2.16K$47.49102.39K
2025-09-09ROBIN HOWARD WSell1.21K$48.1858.30K
2025-09-05ROBIN HOWARD WSell3.30K$37.87125.12K
2025-09-05ROBIN HOWARD WSell2.23K$38.8286.41K
2025-09-05ROBIN HOWARD WSell1.14K$39.8945.32K
2025-09-04Zalevsky JonathanSell793$32.4325.72K
2025-09-04Zalevsky JonathanSell432$33.6014.52K
2025-09-04Zalevsky JonathanSell189$34.416.50K
2025-09-04Zalevsky JonathanSell307$35.6910.96K
2025-09-04ROBIN HOWARD WSell1.92K$32.3762.25K
2025-09-04ROBIN HOWARD WSell1.50K$33.5450.18K
2025-09-04ROBIN HOWARD WSell613$34.4021.09K
2025-09-04ROBIN HOWARD WSell1.13K$35.8040.60K
2025-09-02Zalevsky JonathanSell485$30.1014.60K
2025-09-02ROBIN HOWARD WSell1.50K$30.1645.24K
2025-08-19Zalevsky JonathanSell725$26.5919.28K
2025-08-19Zalevsky JonathanBuy16.67K$0.508.33K
2025-08-19Wilson Mark AndrewBuy21.67K$0.5010.83K
2025-08-19Wilson Mark AndrewSell676$26.5917.97K
2025-08-19ROBIN HOWARD WBuy86.67K$0.5043.33K
2025-08-19ROBIN HOWARD WSell1.57K$26.5941.83K
2025-05-19Zalevsky JonathanSell10.71K$0.677.18K
2025-05-19Wilson Mark AndrewSell10.00K$0.676.70K
2025-05-19ROBIN HOWARD WSell23.21K$0.6715.55K
2025-02-19Zalevsky JonathanSell10.30K$1.0110.40K
2025-02-19Wilson Mark AndrewSell11.04K$1.0111.15K
2025-02-19ROBIN HOWARD WSell23.77K$1.0124.01K
2024-12-24Wilson Mark AndrewSell16.56K$0.8914.74K
2024-12-23Wilson Mark AndrewSell33.40K$0.9030.06K
2024-12-19Zalevsky JonathanSell51.12K$0.9448.05K
2024-12-18ROBIN HOWARD WSell85.03K$0.9984.18K
2024-12-17ROBIN HOWARD WSell46.99K$1.0147.46K
2024-12-13Zalevsky JonathanBuy135.00K——
2024-12-13Zalevsky JonathanBuy375.00K$1.01378.75K
2024-12-13Zalevsky JonathanBuy270.00K$4.911.33M
2024-12-13Wilson Mark AndrewBuy165.94K——
2024-12-13Wilson Mark AndrewBuy331.88K$4.911.63M
2024-12-13Wilson Mark AndrewBuy325.00K$1.01328.25K
2024-12-13ROBIN HOWARD WBuy1.30M$1.011.31M
2024-12-13ROBIN HOWARD WBuy410.62K——
2024-12-13ROBIN HOWARD WBuy821.25K$4.914.03M
2024-11-19Zalevsky JonathanSell7.79K$1.017.86K
2024-11-19Wilson Mark AndrewSell6.41K$1.016.47K
2024-11-19ROBIN HOWARD WSell16.28K$1.0116.44K
2024-09-18WHITFIELD ROY ABuy120.00K$1.26151.20K
2024-09-18GREER R SCOTTBuy120.00K$1.26151.20K
2024-09-18CHESS ROBERTBuy120.00K$1.26151.20K
2024-09-18Brainard DianaBuy120.00K$1.26151.20K
2024-09-18Ajer Jeffrey RobertBuy120.00K$1.26151.20K
2024-08-19Zalevsky JonathanSell6.87K$1.288.79K
2024-08-19Wilson Mark AndrewSell5.65K$1.287.23K
2024-08-19ROBIN HOWARD WSell14.88K$1.2819.05K
2024-06-14CHESS ROBERTSell19.50K$1.2023.40K
2024-05-17ROBIN HOWARD WSell16.65K$1.7529.14K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 258, holders +37 vs prior quarter. Ownership 146.16%.

HolderSharesChangeChange %Value
FMR LLC5.07M764.73K+17.77%353.79M
TWO SEAS CAPITAL LP3.09M1.13M+57.83%215.87M
BLACKROCK, INC.2.94M2.25M+324.72%205.37M
BVF INC/IL2.39M-168.52K-6.58%166.92M
VANGUARD CAPITAL MANAGEMENT LLC1.50M299.79K+25.04%104.50M
TWO SIGMA INVESTMENTS, LP1.20M271.26K+29.14%83.91M
VESTAL POINT CAPITAL, LP1.00M715.00K+250.88%69.81M
MORGAN STANLEY936.56K277.17K+42.03%65.38M
STATE STREET CORP909.68K664.95K+271.71%63.50M
GEODE CAPITAL MANAGEMENT, LLC881.31K534.51K+154.13%61.54M
SUSQUEHANNA INTERNATIONAL GROUP, LLP823.70K602.60K+272.55%57.50M
PROSIGHT MANAGEMENT, LP810.00K75.00K+10.20%56.55M
ARMISTICE CAPITAL, LLC724.00K146.00K+25.26%50.54M
GILDER GAGNON HOWE & CO LLC600.87K329.12K+121.11%41.95M
MILLENNIUM MANAGEMENT LLC478.12K73.84K+18.27%33.38M
BRAIDWELL LP473.62K250.92K+112.67%33.06M
SOFINNOVA INVESTMENTS, INC.471.76K-37.78K-7.42%32.93M
WOODLINE PARTNERS LP470.88K55.54K+13.37%32.87M
ORBIMED ADVISORS LLC465.35K190.35K+69.22%32.49M
UBS GROUP AG428.40K108.23K+33.80%29.91M
SUSQUEHANNA INTERNATIONAL GROUP, LLP394.50K173.40K+78.43%27.54M
EMERALD ADVISERS, LLC390.16K-4.45K-1.13%27.24M
LORD, ABBETT & CO. LLC381.62K-23.46K-5.79%26.64M
VANGUARD PORTFOLIO MANAGEMENT LLC348.54K276.05K+380.80%24.33M
DAFNA CAPITAL MANAGEMENT LLC318.38K153.20K+92.75%22.23M

Earnings and financials

Nektar Therapeutics (NKTR) trades at $38.13, with a market cap of $1.09B and a trailing P/E of -5.66. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
165436000307711000119332300011461700015291500010190700092055000901220009842700055232000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Nektar Therapeutics (NKTR) Financials: Revenue & Earnings

NKTR$38.13+0.16 +0.43%

$1.09B

Market Cap

-5.66

P/E

—

Forward P/E

45

Score

Price History